Q2 2025 Medicure Inc Earnings Call Transcript
Key Points
- Medicure Inc (MCUJF) reported a significant increase in net revenue for Q2 2025, reaching $6.7 million compared to $5.2 million in the previous year.
- The company successfully reduced its net loss to $786,000 from $1.1 million in the previous year, showing improved financial performance.
- Revenue from ZYPITAMAG increased by 21% year-over-year, driven by higher utilization through insurance formularies and sales through Marley Drug.
- The acquisition of Gateway Pharmacy and West Olympia Pharmacy contributed $1.1 million in revenue, expanding Medicure's customer and prescriber base.
- Medicure remains debt-free, providing financial stability and flexibility for future investments and growth opportunities.
- AGGRASTAT revenue decreased slightly due to increased competition from generic alternatives, impacting overall sales.
- The company reported an adjusted EBITDA of negative $28,000, indicating ongoing challenges in achieving profitability.
- Higher cost of goods sold, particularly for Marley Drug, affected profit margins despite increased revenue.
- Research and development expenses remain substantial, with $741,000 spent in Q2 2025, contributing to the net loss.
- The cash balance decreased from $7.2 million at the end of 2024 to $4.8 million as of June 30, 2025, primarily due to recent acquisitions.
Welcome to Medicure's earnings conference call for the quarter ended December 30, 2025. My name is Holly, and I will be your operator for today's call. (Operator Instructions)
Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events and expectations, which are made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20-F.
Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded, and today's date is August 21, 2025.
I would like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicure Inc. Please go ahead, Dr. Friesen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
